EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 41 / No 10 (Octobre 2025) Med Sci (Paris), 41 10 (2025) 753-759 References
Open Access
Issue
Med Sci (Paris)
Volume 41, Number 10, Octobre 2025
Page(s) 753 - 759
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2025141
Published online 19 November 2025
  1. Fiscutean A. Clarifying the burden of ovarian cancer. Nature 2021 ; 600 : S48–9. [Google Scholar]
  2. Arnaoutoglou C, Dampala K, Anthoulakis C, et al. Epithelial ovarian cancer: a five year review. Medicina 2023 ; 59 : 1183. [Google Scholar]
  3. Sambasivan S. Epithelial ovarian cancer: review article. Cancer Treat Res Commun 2022 ; 33 : 100629. [Google Scholar]
  4. Arora T, Mullangi S, Vadakekut ES, et al. Epithelial ovarian cancer. StatPearls. Treasure Island (FL) : StatPearls Publishing, 2025 : [Google Scholar]
  5. Tavares V, Marques IS, Melo IG de, et al. Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements. Inter J Mol Sci 2024 ; 25 : 1845. [Google Scholar]
  6. Casini A, Pöthig A. Metals in cancer research: beyond platinum metallodrugs. ACS Cent Sci 2024 ; 10 : 242–50. [Google Scholar]
  7. Mjos KD, Orvig C. Metallodrugs in medicinal inorganic chemistry. Chem Rev 2014 ; 114 : 4540–63. [Google Scholar]
  8. Wei F, Liang J, Shen X-C, et al. Recent advances in the development of metallodrugs for cancer chemoimmunotherapy. Coordi Chem Rev 2025 ; 526 : 216319. [Google Scholar]
  9. Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem 2019 ; 88 : 102925. [Google Scholar]
  10. Gold JM, Raja A. Cisplatin. StatPearls. Treasure Island (FL) : StatPearls Publishing, 2025 : [Google Scholar]
  11. Tchounwou PB, Dasari S, Noubissi FK, et al. Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy. J Exp Pharmacol 2021 ; 13 : 303–28. [Google Scholar]
  12. Rossi A. Relapsed small-cell lung cancer: platinum re-challenge or not. J Thor Dis 2016 ; 8. [Google Scholar]
  13. Balfourier A, Kolosnjaj-Tabi J, Luciani N, et al. Gold-based therapy: From past to present. Proc Natl Acad Sci USA 2020 ; 117 : 22639–48. [Google Scholar]
  14. Groessl M, Reisner E, Hartinger CG, et al. Structure−activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L (S-dmso)ruthenate (III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity. J Med Chem 2007 ; 50 : 2185–93. [Google Scholar]
  15. Spratlin JL, O’Kane GM, Oh D-Y, et al. BOLD-100-001 (TRIO039): a phase 2 study of BOLD-100 in combination with FOLFOX in patients with advanced mCRC previously treated with FOLFOX/CAPOX— Efficacy and safety analysis. JCO 2024 ; 42 : 143. [Google Scholar]
  16. Jaouen G, Vessières A, Top S. Ferrocifen type anti cancer drugs. Chem Soc Rev 2015 ; 44 : 8802–17. [Google Scholar]
  17. Wang Y, Pigeon P, Li W, et al. Diversity-oriented synthesis and bioactivity evaluation of N-substituted ferrocifen compounds as novel antiproliferative agents against TNBC cancer cells. Eur J Med Chem 2022 ; 234 : 114202. [Google Scholar]
  18. Maillet A, Yadav S, Loo YL, et al. A novel Osmium-based compound targets the mitochondria and triggers ROS-dependent apoptosis in colon carcinoma. Cell Death Dis 2013 ; 4 : e653. [Google Scholar]
  19. Dieckmann S, Riedel R, Harms K, et al. Pyridocarbazole-rhodium (III) complexes as protein kinase inhibitors. Eur J Inorg Chem 2012 ; 2012 : 813–21. [Google Scholar]
  20. Boros E, Dyson PJ, Gasser G. Classification of metal-based drugs according to their mechanisms of action. Chem 2020 ; 6 : 41–60. [Google Scholar]
  21. Adhikari S, Nath P, Das A, et al. A review on metal complexes and its anti-cancer activities: Recent updates from in vivo studies. Biomed Pharmacother 2024 ; 171 : 116211. [Google Scholar]
  22. Alessio E, Messori L. NAMI-A and KP1019/1339, Two iconic ruthenium anticancer drug candidates face-to-face: a case story in medicinal inorganic chemistry. Molecules 2019 ; 24 : 1995. [Google Scholar]
  23. Chen Q, Ramu V, Aydar Y, et al. TLD1433 Photosensitizer inhibits conjunctival melanoma cells in zebrafish ectopic and orthotopic tumour models. Cancers 2020 ; 12 : 587. [Google Scholar]
  24. Oliveira KM, Honorato J, Demidoff FC, et al. Lapachol in the design of a new ruthenium (II)- diphosphine complex as a promising anticancer metallodrug. J Inorg Biochem 2021 ; 214 : 111289. [Google Scholar]
  25. Sumithaa C, Ganeshpandian M. Half-Sandwich Ruthenium arene complexes bearing clinically approved drugs as ligands: the importance of metal-drug synergism in metallodrug design. Mol Pharm 2023 ; 20 : 1453–79. [Google Scholar]
  26. Notaro A, Frei A, Rubbiani R, et al. Ruthenium (II) complex containing a redox-active semiquinonate ligand as a potential chemotherapeutic agent: from synthesis to in vivo studies. J. Med. Chem. 2020 ; 63 : 5568–84. [Google Scholar]
  27. Beach MA, Nayanathara U, Gao Y, et al. Polymeric nanoparticles for drug delivery. Chem. Rev. 2024 ; 124 : 5505–616. [Google Scholar]
  28. Dantas KCF, Rosário J dos S, Silva-Caldeira PP. Polymeric nanosystems applied for metal-based drugs and photosensitizers delivery: the state of the art and recent advancements. Pharmaceutics 2022 ; 14 : 1506. [Google Scholar]
  29. Kumar Sahu AK, Kashyap P, Yadav R, et al. Properties and Applications of Ruthenium. In : Seehra MS, Bristow AD, eds. Noble and Precious Metals - Properties, Nanoscale Effects and Applications. Rijeka : IntechOpen, 2018. [Google Scholar]
  30. Lin K, Zhao Z-Z, Bo H-B, et al. Applications of ruthenium complex in tumor diagnosis and therapy. Front Pharmacol 2018 ; 9. [Google Scholar]
  31. Thota S, Rodrigues DA, Crans DC, et al. Ru (II) compounds: next-generation anticancer metallotherapeutics? J Med Chem 2018 ; 61 : 5805–21. [Google Scholar]
  32. Antonarakis ES, Emadi A. Ruthenium-based chemotherapeutics: are they ready for prime time? Cancer Chemother Pharmacol 2010 ; 66 : 1–9. [Google Scholar]
  33. Zeng L, Gupta P, Chen Y, et al. The development of anticancer ruthenium (ii) complexes: from single molecule compounds to nanomaterials. Chem Soc Rev 2017 ; 46 : 5771–804. [Google Scholar]
  34. Wan D, Tang B, Wang Y-J, et al. Synthesis and anticancer properties of ruthenium (II) complexes as potent apoptosis inducers through mitochondrial disruption. Eur J Med Chem 2017 ; 139 : 180–90. [Google Scholar]
  35. Hoye AT, Davoren JE, Wipf P, et al. Targeting mitochondria. Acc Chem Re. 2008 ; 41 : 87–97. [Google Scholar]
  36. Yousif LF, Stewart KM, Kelley SO. Targeting mitochondria with organelle-specific compounds: strategies and applications. Chembiochem 2009 ; 10 : 1939–50. [Google Scholar]
  37. Zhang W, Chen W, Fu F, et al. Mitochondria-targeted ruthenium (II) complexes for photodynamic therapy and GSH detection in living cells. Dalton Trans 2024 ; 53 : 5957–65. [Google Scholar]
  38. Brabec V, Nováková O. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resist Updat 2006 ; 9 : 111–22. [Google Scholar]
  39. Bruce MI, Costuas K, Davin T, et al. Iron versus ruthenium: dramatic changes in electronic structure result from replacement of one fe by ru in [{Cp*(dppe)Fe}-CC-CC-{Fe (dppe)Cp*}]n + (n = 0, 1, 2). Organometallics 2005 ; 24 : 3864–81. [Google Scholar]
  40. Gatter KC, Brown G, Trowbridge IS, et al. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 1983 ; 36 : 539–45. [Google Scholar]
  41. Notaro A, Jakubaszek M, Rotthowe N, et al. Increasing the cytotoxicity of ru (ii) polypyridyl complexes by tuning the electronic structure of dioxo ligands. J Am Chem Soc 2020 ; 142 : 6066–84. [Google Scholar]
  42. Handbook of Pharmaceutical Excipients – 7th Edition Pharmaceutical Development and Technology 2013 ; 18 : 544. [Google Scholar]
  43. Schwartzberg LS, Navari RM. Safety of polysorbate 80 in the oncology setting. Adv Ther 2018 ; 35 : 754–67. [Google Scholar]
  44. Sung YK, Kim SW. Recent advances in polymeric drug delivery systems. Biomater Res 2020 ; 24 : 12. [Google Scholar]
  45. Elumalai K, Srinivasan S, Shanmugam A. Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment. Biomed Tech 2024 ; 5 : 109–22. [Google Scholar]
  46. Idrees H, Zaidi SZJ, Sabir A, et al. A review of biodegradable natural polymer-based nanoparticles for drug delivery applications. Nanomaterials (Basel) 2020 ; 10 : 1970. [Google Scholar]
  47. Redrado M, Xiao Z, Upitak K, et al. Applications of biodegradable polymers in the encapsulation of anticancer metal complexes. Adv Funct Mater 2024 ; 34 : 2401950. [Google Scholar]
  48. Klojdová I, Milota T, Smetanová J, et al. Encapsulation: A Strategy to Deliver Therapeutics and Bioactive Compounds? Pharmaceutic 2023 ; 16 : 362. [Google Scholar]
  49. Villemin E, Ong YC, Thomas CM, et al. Polymer encapsulation of ruthenium complexes for biological and medicinal applications. Nat Rev Chem 2019 ; 3 : 261–82. [Google Scholar]
  50. Karges J. Encapsulation of Ru (II) Polypyridine complexes for tumor-targeted anticancer therapy. BME Frontiers 2023 ; 4 : 0024. [Google Scholar]
  51. António JPM, Gandioso A, Nemati F, et al. Polymeric encapsulation of a ruthenium (II) polypyridyl complex: from synthesis to in vivo studies against high-grade epithelial ovarian cancer. Chem Sci 2023 ; 14 : 362–71. [Google Scholar]
  52. Soliman N, McKenzie LK, Karges J, et al. Ruthenium-initiated polymerization of lactide: a route to remarkable cellular uptake for photodynamic therapy of cancer. Chem Sci 2020 ; 11 : 2657–63. [Google Scholar]
  53. Soliman N, Sol V, Ouk T-S, et al. Encapsulation of a Ru (II) polypyridyl complex into polylactide nanoparticles for antimicrobial photodynamic therapy. Pharmaceutics 2020 ; 12 : 961. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.